Neupro Approval History

Neupro (rotigotine) is a dopamine agonist transdermal system indicated for the treatment of Parkinson’s disease and Restless Legs Syndrome.

FDA Approval History for Neupro

DateArticle
Apr  3, 2012Approval Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome
May 10, 2007Approval FDA Approves Schwarz Pharma's Neupro (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease in USA
Mar  1, 2006Neupro Receives Approvable Letter from FDA for Early Parkinson's Disease in USA
Jan 28, 2005Schwarz Pharma Re-Submits NDA for Rotigotine in the U.S.
Sep 29, 2004Schwarz Pharma Submits Marketing Applications for its Rotigotine Patch 'Neupro'

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)